Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Precision BioSciences, Inc. (DTIL : NSDQ)

• Company Description    Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. Number of Employees: 68

• Price / Volume Information    Yesterday's Closing Price: $7.29 Daily Weekly Monthly 20 Day Moving Average: 663,807 shares Shares Outstanding: 25.80 (millions) Market Capitalization: $188.10 (millions) Beta: 1.25 52 Week High: $9.62 52 Week Low: $3.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.00% 7.21% 12 Week 1.96% -0.83% Year To Date 75.24% 62.82%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 302 EAST PETTIGREW STREET SUITE A-100 - DURHAM,NC 27701 USA ph: 919-314-5512 fax: - ir@precisionbiosciences.com http://www.precisionbiosciences.com

• General Corporate Information    Officers Michael Amoroso - President; Chief Executive Officer and Director Kevin Buehler - Chairman and Director John Alexander Kelly - Chief Financial Officer Melinda Brown - Director Stanley Frankel - Director Peer Information Precision BioSciences, Inc. (CORR.) Precision BioSciences, Inc. (RSPI) Precision BioSciences, Inc. (CGXP) Precision BioSciences, Inc. (BGEN) Precision BioSciences, Inc. (GTBP) Precision BioSciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74019P207 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 25.80 Most Recent Split Date: 2.00 (0.03:1) Beta: 1.25 Market Capitalization: $188.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.21 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.47 Price/Cash Flow: - Price / Sales: 4.17 EPS Growth vs. Year Ago Period: 84.62% vs. Previous Quarter: -194.44% Sales Growth vs. Year Ago Period: 37,272.41% vs. Previous Quarter: -68.31% ROE 06/30/26 - - 03/31/26 - -85.37 12/31/25 - -122.60 ROA 06/30/26 - - 03/31/26 - -37.34 12/31/25 - -48.98 Current Ratio 06/30/26 - - 03/31/26 - 14.02 12/31/25 - 13.32 Quick Ratio 06/30/26 - - 03/31/26 - 14.02 12/31/25 - 13.32 Operating Margin 06/30/26 - - 03/31/26 - -103.72 12/31/25 - -171.99 Net Margin 06/30/26 - - 03/31/26 - -96.73 12/31/25 - -133.45 Pre-Tax Margin 06/30/26 - - 03/31/26 - -98.69 12/31/25 - -136.03 Book Value 06/30/26 - - 03/31/26 - 2.95 12/31/25 - 4.03 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.29 12/31/25 - 0.24 Debt-to-Capital 06/30/26 - - 03/31/26 - 22.76 12/31/25 - 19.54

Powered by Zacks Investment Research ©